Manik Chhabra, Evan C Lewis, Robert Balshaw, Breanne Stewart, Zina Zaslawski, Trinity Lowthian, Zahra Alidina, Melila Chesick-Gordis, Wenli Xie, Britt I Drögemöller, Galen E B Wright, Kathryn A Birnie, Katelynn E Boerner, Vivian W L Tsang, Samantha Lee Irwin, Daniela Pohl, Alexander G Weil, Erick Sell, Erika Penz, Amy Robson-MacKay, Sophia Mbabaali, Stephanie Blackman, Shanlea Gordon, Jane Alcorn, Richard J Huntsman, Tim F Oberlander, G Allen Finley, Lauren E Kelly
{"title":"A multi-centre, tolerability study of a cannabidiol-enriched Cannabis Herbal Extract for chronic headaches in adolescents: The CAN-CHA protocol.","authors":"Manik Chhabra, Evan C Lewis, Robert Balshaw, Breanne Stewart, Zina Zaslawski, Trinity Lowthian, Zahra Alidina, Melila Chesick-Gordis, Wenli Xie, Britt I Drögemöller, Galen E B Wright, Kathryn A Birnie, Katelynn E Boerner, Vivian W L Tsang, Samantha Lee Irwin, Daniela Pohl, Alexander G Weil, Erick Sell, Erika Penz, Amy Robson-MacKay, Sophia Mbabaali, Stephanie Blackman, Shanlea Gordon, Jane Alcorn, Richard J Huntsman, Tim F Oberlander, G Allen Finley, Lauren E Kelly","doi":"10.1371/journal.pone.0290185","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Cannabis products have been used in the management of headaches in adults and may play a role in pediatric chronic pain. Canadian pediatricians report increasing use of cannabis for the management of chronic headaches, despite no well-controlled studies to inform its dosing, safety, and effectiveness. The aim of our clinical trial is to determine the dosing and safety of a Cannabidiol (CBD)-enriched Cannabis Herbal Extract (CHE) for the treatment of chronic headaches in adolescents.</p><p><strong>Methods and analysis: </strong>Youth, parents, and an expert steering committee co-designed this tolerability study. Twenty adolescents (aged 14 to 17 years), with a chronic migraine diagnosis for more than 6 months that has not responded to other therapies will be enrolled into an open label, dose escalation study across three Canadian sites. Study participants will receive escalating doses of a CBD-enriched CHE (MPL-001 with a THC:CBD of 1:25), starting at 0.2-0.4 mg/kg of CBD per day and escalating monthly up to 0.8-1.0 mg/kg of CBD per day. The primary objective of this study is to determine the safety and tolerability of CBD-enriched CHE in adolescents with chronic migraine. Secondary objectives of this study will inform the development of subsequent randomized controlled trials and include investigating the relationship between the dose escalation and change in the frequency of headache, impact and intensity of pain, changes in sleep, mood, function, and quality of life. Exploratory outcomes include investigating steady-state trough plasma levels of bioactive cannabinoids and investigating how pharmacogenetic profiles affect cannabinoid metabolism among adolescents receiving CBD-enriched CHE.</p><p><strong>Discussion: </strong>This protocol was co-designed with youth and describes a tolerability clinical trial of CBD-enriched CHE in adolescents with chronic headaches that have not responded to conventional therapies. This study is the first clinical trial on cannabis products in adolescents with chronic headaches and will inform the development of future comparative effectiveness clinical trials.</p><p><strong>Trial registration: </strong>CAN-CHA trial is registered with ClinicalTrials.gov with a number of register NCT05337033.</p>","PeriodicalId":20189,"journal":{"name":"PLoS ONE","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11414974/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PLoS ONE","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1371/journal.pone.0290185","RegionNum":3,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Cannabis products have been used in the management of headaches in adults and may play a role in pediatric chronic pain. Canadian pediatricians report increasing use of cannabis for the management of chronic headaches, despite no well-controlled studies to inform its dosing, safety, and effectiveness. The aim of our clinical trial is to determine the dosing and safety of a Cannabidiol (CBD)-enriched Cannabis Herbal Extract (CHE) for the treatment of chronic headaches in adolescents.
Methods and analysis: Youth, parents, and an expert steering committee co-designed this tolerability study. Twenty adolescents (aged 14 to 17 years), with a chronic migraine diagnosis for more than 6 months that has not responded to other therapies will be enrolled into an open label, dose escalation study across three Canadian sites. Study participants will receive escalating doses of a CBD-enriched CHE (MPL-001 with a THC:CBD of 1:25), starting at 0.2-0.4 mg/kg of CBD per day and escalating monthly up to 0.8-1.0 mg/kg of CBD per day. The primary objective of this study is to determine the safety and tolerability of CBD-enriched CHE in adolescents with chronic migraine. Secondary objectives of this study will inform the development of subsequent randomized controlled trials and include investigating the relationship between the dose escalation and change in the frequency of headache, impact and intensity of pain, changes in sleep, mood, function, and quality of life. Exploratory outcomes include investigating steady-state trough plasma levels of bioactive cannabinoids and investigating how pharmacogenetic profiles affect cannabinoid metabolism among adolescents receiving CBD-enriched CHE.
Discussion: This protocol was co-designed with youth and describes a tolerability clinical trial of CBD-enriched CHE in adolescents with chronic headaches that have not responded to conventional therapies. This study is the first clinical trial on cannabis products in adolescents with chronic headaches and will inform the development of future comparative effectiveness clinical trials.
Trial registration: CAN-CHA trial is registered with ClinicalTrials.gov with a number of register NCT05337033.
期刊介绍：
PLOS ONE is an international, peer-reviewed, open-access, online publication. PLOS ONE welcomes reports on primary research from any scientific discipline. It provides:
* Open-access—freely accessible online, authors retain copyright
* Fast publication times
* Peer review by expert, practicing researchers
* Post-publication tools to indicate quality and impact
* Community-based dialogue on articles
* Worldwide media coverage
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
